Unknown PHASE4 INTERVENTIONAL 2-arm NCT03005236

AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING)

AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study

Sponsor: University Hospital Birmingham NHS Foundation Trust

Conditions Kidney Transplant Failure and Rejection

Interventions ENVARSUS Standard twice daily tacrolimus

Updated 7 times since 2017 Last updated: Dec 28, 2016 Started: Apr 30, 2017 Primary completion: Apr 30, 2019 Completion: Oct 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Kidney Transplant Failure and Rejection, this trial is ongoing. The trial is conducted by University Hospital Birmingham NHS Foundation Trust and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Nov 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Nov 2019 [monthly]

Not Yet Recruiting PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital Birmingham NHS Foundation Trust

Data source: University Hospital Birmingham NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.